Six DMRs located on HOXA9, HOXD3, PCDH17, NID2, NPTX2, and SFRP2 genes exhibiting clinical accuracy over 75% irrespective of lung cancer subtype and cancer progression stages were selected as lung cancer-specific exosome DNA methylation biomarkers. This evidence concerns the gene SFRP2 and lung carcinoma.